|Table of Contents|

Effect of androgen receptor-regulated long non-coding RNA ARLNC1 on proliferation,clone,migration and cell cycle of prostate cancer cells

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 02
Page:
220-226
Research Field:
Publishing date:

Info

Title:
Effect of androgen receptor-regulated long non-coding RNA ARLNC1 on proliferation,clone,migration and cell cycle of prostate cancer cells
Author(s):
ZHENG Jiangting; YIN Ye; CUN Shu' e; WANG Yuming
Department of Clinical Laboratory,the Second Affiliated Hospital of Kunming Medical University,Yunnan Kunming 650000,China.
Keywords:
prostate cancer; long non-coding RNA; androgen receptor; proliferation; clone; migration; cell cycle
PACS:
R737.25
DOI:
10.3969/j.issn.1672-4992.2024.02.004
Abstract:
Objective:To investigate the effect of androgen receptor (AR)-regulated long non-coding RNA (lncRNA) ARLNC1 on the proliferation,clone,migration and cell cycle of prostate cancer cells.Methods:Normal prostate epithelial cell line WPMY-1 and prostate cancer cell lines PC3,VCaP,22RV1,DU145 and LNCaP were selected as the study objects.The expression level of lncRNA ARLNC1 was analyzed by qRT-PCR.Dihydrotestosterone (DHT) stimulated LNCaP cells in a time-and concentration-dependent manner to analyze the transcription level of lncRNA ARLNC1.The relationship between the androgen receptor and lncRNA ARLNC1 was analyzed by using database prediction and dual luciferase reporter system.LNCaP cells were divided into sh-NC group and sh-lncRNA ARLNC1 group.CCK-8 was used to analyze cell proliferation.The cell cloning and migration ability were detected.The cell cycle changes were analyzed by flow cytometry,and the expression levels of CyclinD1,CDK6 and p27 were analyzed by Western blot.Results:Compared with normal prostate epithelial cells,lncRNA ARLNC1 expression was significantly increased in androgen-dependent prostate cancer cell lines (LNCaP,VCaP,22RV1),but hardly expressed in androgen-independent prostate cancer cell lines (PC3,DU145) (P＜0.05).LNCaP cells had the most significant changes,so LNCaP cells were selected as the experimental strain next time.After 100 nmol/L DHT stimulation of LNCaP cells for 0,6,12,18 and 24 h,the transcription level of lncRNA ARLNC1 was increased in a time-dependent manner compared with the control group (P＜0.05).lncRNA ARLNC1 transcription levels increased with different concentrations (0,0.1,1,10,100 nmol/L) of DHT stimulated LNCaP cells for 24 h (P＜0.05).The JASPAR database predicted that there were AR binding sites in lncRNA ARLNC1 promoter region,and the dual luciferase reporter system showed that AR could bind to lncRNA ARLNC1 promoter region and activate its transcription (P＜0.05).Compared with sh-NC group,the cell proliferation,migration and cloning ability of sh-lncRNA ARLNC1 group were weakened,and the cell cycle was arrested in S and G2 phases (P＜0.05).Compared with sh-lncRNA ARLNC1 group,the protein levels of CyclinD1 and CDK6 in sh-NC group were increased,while the protein level of p27 was decreased (P＜0.05).Conclusion:lncRNA ARLNC1 regulated by AR is highly expressed as an oncogene in androgen receptor-positive prostate cancer cell lines,which can promote the proliferation,cloning,migration and cell cycle progression of prostate cancer cells.

References:

[1] TANEJA SS.Urological oncology:prostate cancer［J］.J Urol,2021,206(2):476-479.
[2] KOTAMARTI S,ARMSTRONG AJ,POLASCIK TJ,et al.Molecular mechanisms of castrate-resistant prostate cancer［J］.Urol Clin North Am,2022,49(4):615-626.
[3] HARRIS AE,METZLER VM,LOTHION-ROY J,et al.Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer［J］.Front Endocrinol (Lausanne),2022,13:1006101.
[4] SHI ZF,CHEN J,WUMANER A,et al.A novel long non-coding RNA PCLN16 facilitates androgen receptor signaling in prostate cancer［J］.Biochem Biophys Res Commun,2021,5（37）:78-84.
[5] LIANG D,TIAN CJ,ZHANG XW.lncRNA MNX1-AS1 promotes prostate cancer progression through regulating miR-2113/MDM2 axis［J］.Mol Med Rep,2022,26(1)：261-270.
[6] KARTHIKEYAN SK,XU N,FERGUSON RJ,et al.Identification of androgen response-related lncRNAs in prostate cancer［J］.Prostate,2023,83(6):590-601.
[7] SIEGEL RL,WAGLE NS,CERCEK,et al.Colorectal cancer statistics,2023［J］.CA-Cancer J Clin,2023,73(3):233-254.
[8] WANG EC,LEE WR,ARMSTRONG AJ.Second generation anti-androgens and androgen deprivation therapy with radiation therapy in the definitive management of high-risk prostate cancer［J］.Prostate Cancer Prostatic Dis,2023,26(1):30-40.
[9] JI Y,ZHANG RU,HAN XL,et al.Targeting the N-terminal domain of the androgen receptor:The effective approach in therapy of CRPC［J］.Eur J Med Chem,2023,247（11）：50-77.
[10] CARAMELLA I,DALLA VA,BERGAMINI M,et al.Maintenance of androgen deprivation therapy or testosterone supplementation in the management of castration-resistant prostate cancer:that is the question［J］.Endocrine,2022,78(3):441-445.
[11] NAITO Y,KATO M,KAWANISHI H,et al.Clinical utility of intraductal carcinoma of the prostate in treatment selection for metastatic hormone-sensitive prostate cancer［J］.Prostate,2023,83(4):307-315.
[12] ZHANG M,SUN Y,HUANG CP,et al.Targeting the Lnc-OPHN1-5/androgen receptor/hnRNPA1 complex increases Enzalutamide sensitivity to better suppress prostate cancer progression［J］.Cell Death Dis,2021,12(10):855-865.
[13] LI ZH,TENG JF,JIA ZM,et al.The long non-coding RNA PCAL7 promotes prostate cancer by strengthening androgen receptor signaling［J］.Journal of Clinical Laboratory Analysis,2021,35(2)：749-757.
[14] KUMAR S,PRAJAPATI KS,SINGH AK,et al.Long non-coding RNA regulating androgen receptor signaling in breast and prostate cancer［J］.Cancer Lett,2021,504(1):15-22.
[15] ZHANG BY,ZHANG MP,SHEN CY,et al.LncRNA PCBP1-AS1-mediated AR/AR-V7 deubiquitination enhances prostate cancer enzalutamide resistance［J］.Cell Death Dis,2021,12(10):856-862.
[16] ZHANG BY,PITCHIAYA S,CIESLIK M,et al.Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression［J］.Nature Genetics,2018,50(6):814-824.
[17] HUSEYNOVA G,ZGR E,BILGICGAZIOGLU S,et al.Androgen receptor blockade using enzalutamide suppresses long non-coding RNA ARLNC1 in prostate cancer cells［J］.Cell Journal (Yakhteh),2022,24(12):774-778.

Memo

Memo:
云南省科技人才和平台计划（编号：2019IC034）；昆明医科大学第二附属医院院内科技计划资助项目（编号：2020yk004）
Last Update: 1900-01-01